CTRI/2020/10/028556进行中（未招募）4 期
A, multicentre, prospective, open labeled phase IV study to evaluate safety andefficacy of Dienogest in patients suffering from endometriosis
Jagsonpal Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Patients with a confirmed diagnosis of Endometriosis based on laparoscopy or
- •2.Patients who receive a prescription of DIENOGEST according to the
- •indication stated in the local approved SmPC.
- •3.Written informed consent signed by the patient or legally acceptable
- •representative(s) in line with applicable re.gulation of country.
- •4.Planned treatment in line with the Summary of Product Characteristics, i.e.
- •exclusion of all patients with contraindications.
排除标准
- •1.Exclusion of all patients with contraindications as per Investigators discretion
研究者
相似试验
进行中（未招募）
4 期
Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne VulgarisCTRI/2021/06/034069GALDERMA India Pvt Ltd
招募中
4 期
A prospective phase IV studyto evaluate safety and efficacy profile of DenosteRel® in post-menopausal women with osteoporosisCTRI/2024/03/064638Reliance Life Sciences Pvt Ltd RLS
进行中（未招募）
4 期
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as Infimabâ?¢ in patients with moderate to severe plaque psoriasis which is a skin disease characterized by raised red patches covered with a silvery white buildup of dead skincells or scaleCTRI/2019/09/021078Reliance Life Sciences Pvt Ltd
已完成
4 期
The post marketing clinical research on drug Infliximab in patients with moderate to severe Crohn’s diseaseCTRI/2018/03/012298Reliance Life Sciences Pvt Ltd100
进行中（未招募）
4 期
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as AdaliRel�® in patients with moderate to severe plaque psoriasis which is a skin disease characterized by raised red patches covered with a silvery white buildup of dead skin cells or scaleCTRI/2019/10/021694Reliance Life Sciences Pvt Ltd RLS